Duchenne muscular dystrophy

Journal of Paediatrics and Child Health

Volumn 51, Issue 8, 2015, Pages 759-764

  Yiu, Eppie M ^a,b,c   Kornberg, Andrew J ^a,b,c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

corticosteroid; Duchenne; gene therapy; muscular dystrophy; non invasive ventilation; positive pressure

Indexed keywords

ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ATALUREN; CORTICOSTEROID; CREATINE KINASE; DEFLAZACORT; DYSTROPHIN; MESSENGER RNA; PLACEBO; PREDNISOLONE; PREDNISONE;

BONE DENSITY; BREATHING EXERCISE; CARDIOPULMONARY INSUFFICIENCY; CHILDHOOD; CLINICAL FEATURE; CONTRACTURE; CREATINE KINASE BLOOD LEVEL; DISEASE SURVEILLANCE; DMD GENE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FUNCTIONAL STATUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; HETEROZYGOTE; HUMAN; INTERMITTENT POSITIVE PRESSURE VENTILATION; KINESIOTHERAPY; LIFE EXPECTANCY; LOW DRUG DOSE; LUNG FUNCTION TEST; MOBILIZATION; MOLECULAR GENETICS; MORBIDITY; MUSCLE BIOPSY; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; SCOLIOSIS; SPINE SURGERY; WHEELCHAIR; ADOLESCENT; CHILD; GENETICS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PATHOPHYSIOLOGY;

ADOLESCENT; CHILD; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84938200444     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/jpc.12868     Document Type: Review

References (48)

1. Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L,. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur. J. Hum. Genet. 2013; 21: 1049-1053.
2. Eagle M, Bourke J, Bullock R, et al. Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul. Disord. 2007; 17: 470-475.
3. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K,. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul. Disord. 2002; 12: 926-929.
4. Darras BT, Menache-Starobinski CC, Hinton V, Kunkel LM,. Dystrophinopathies. Chapter 30. In:, Darras BT, Jones H, Ryan M, De Vivo DC, eds. Neuromuscular Disorders of Infancy, Childhood, and Adolescence A Clinicians Approach, 2nd edn. London: Elsevier, 2015; 551-592.
5. Nigro G, Comi LI, Politano L, Bain RJ,. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol. 1990; 26: 271-277.
6. Khirani S, Ramirez A, Aubertin G, et al. Respiratory muscle decline in Duchenne muscular dystrophy. Pediatr. Pulmonol. 2014; 49: 473-481.
7. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM,. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am. J. Respir. Crit. Care Med. 2001; 164: 2191-2194.
8. Suresh S, Wales P, Dakin C, Harris M-A, Cooper DGM,. Sleep-related breathing disorder in Duchenne muscular dystrophy: disease spectrum in the paediatric population. J. Paediatr. Child Health 2005; 41: 500-503.
9. Ragette R, Mellies U, Schwake C, Voit T, Teschler H,. Patterns and predictors of sleep disordered breathing in primary myopathies. Thorax 2002; 57: 724-728.
10. Leibowitz D, Dubowitz V,. Intellect and behaviour in Duchenne muscular dystrophy. Dev. Med. Child Neurol. 1981; 23: 577-590.
11. Hendriksen JG, Vles JS,. Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder. J. Child Neurol. 2008; 23: 477-481.
12. Smith AD, Koreska J, Moseley CF,. Progression of scoliosis in Duchenne muscular dystrophy. J. Bone Joint Surg. Am. 1989; 71: 1066-1074.
13. Rodillo EB, Fernandez-Bermejo E, Heckmatt JZ, Dubowitz V,. Prevention of rapidly progressive scoliosis in Duchenne muscular dystrophy by prolongation of walking with orthoses. J. Child Neurol. 1988; 3: 269-274.
14. King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007; 68: 1607-1613.
15. Birnkrant DJ,. The American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Pediatrics 2009; 123 (Suppl. 4): S242-244.
16. Hayes J, Veyckemans F, Bissonnette B,. Duchenne muscular dystrophy: an old anesthesia problem revisited. Paediatr. Anaesth. 2008; 18: 100-106.
17. Hoffman EP, Brown RH Jr, Kunkel LM,. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
18. Kunkel LM, Hejtmancik JF, Caskey CT, et al. Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 1986; 322: 73-77.
19. Rando TA,. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 2001; 24: 1575-1594.
20. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT,. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34: 135-144.
21. Deconinck N, Dan B,. Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr. Neurol. 2007; 36: 1-7.
22. Hoffman EP, Fischbeck KH, Brown RH, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N. Engl. J. Med. 1988; 318: 1363-1368.
23. Laing NG, Davis MR, Bayley K, Fletcher S, Wilton SD,. Molecular diagnosis of duchenne muscular dystrophy: past, present and future in relation to implementing therapies. Clin. Biochem. Rev. 2011; 32: 129-134.
24. Hoogerwaard EM, Bakker E, Ippel PF, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 1999; 353: 2116-2119.
25. Hoogerwaard EM, van der Wouw PA, Wilde AA, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul. Disord. 1999; 9: 347-351.
26. Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012; 31: 121-125.
27. Rall S, Grimm T,. Survival in Duchenne muscular dystrophy. Acta Myol. 2012; 31: 117-120.
28. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010; 9: 177-189.
29. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010; 9: 77-93.
30. Manzur AY, Kuntzer T, Pike M, Swan A,. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst. Rev. 2004; (2): CD003725, update of, PMID: 15106215]. Cochrane Database Syst Rev 2008: CD003725.
31. Moxley RT III, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64: 13-20.
32. Balaban B, Matthews DJ, Clayton GH, Carry T,. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am. J. Phys. Med. Rehabil. 2005; 84: 843-850.
33. Biggar WD, Harris VA, Eliasoph L, Alman B,. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul. Disord. 2006; 16: 249-255.
34. Daftary AS, Crisanti M, Kalra M, Wong B, Amin R,. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics 2007; 119: e320-324.
35. Birnkrant DJ, Bushby KM, Amin RS, et al. The respiratory management of patients with duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr. Pulmonol. 2010; 45: 739-748.
36. Toussaint M, Steens M, Wasteels G, Soudon P,. Diurnal ventilation via mouthpiece: survival in end-stage Duchenne patients. Eur. Respir. J. 2006; 28: 549-555. see comment.
37. American Academy of Pediatrics Section on C, Cardiac S,. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 2005; 116: 1569-1573. see comment.
38. Kinali M, Main M, Eliahoo J, et al. Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. Eur. J. Paediatr. Neurol. 2007; 11: 160-166.
39. Velasco MV, Colin AA, Zurakowski D, Darras BT, Shapiro F,. Posterior spinal fusion for scoliosis in duchenne muscular dystrophy diminishes the rate of respiratory decline. Spine 2007; 32: 459-465.
40. Davidson ZE, Truby H,. A review of nutrition in Duchenne muscular dystrophy. J. Hum. Nutr. Diet. 2009; 22: 383-393.
41. Nolan MA, Jones OD, Pedersen RL, Johnston HM,. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul. Disord. 2003; 13: 129-132.
42. Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann. Neurol. 2012; 71: 304-313.
43. Parsons EP, Clarke AJ, Hood K, Lycett E, Bradley DM,. Newborn screening for Duchenne muscular dystrophy: a psychosocial study. Arch. Dis. Child. Fetal Neonatal Ed. 2002; 86: F91-95.
44. Pichavant C, Aartsma-Rus A, Clemens PR, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol. Ther. 2011; 19: 830-840.
45. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91.
46. Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 2014; 50: 477-487.
47. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 2013; 74: 637-647.
48. Voit T, Topaloglu H, Straub V, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014; 13: 987-996.